Abstract
Liver metastasis remains a significant challenge in treating colorectal and gastric cancers. This study, published in Frontiers in Oncology, investigates the efficacy and safety of intratumoral oncolytic virus (OV) injections combined with chemotherapy. Analyzing 47 patients, the researchers evaluated clinical outcomes and the impact of a structured nursing protocol on managing adverse reactions. Results showed a 74.5% disease control rate, with manageable side effects such as fever and pain. The study concludes that comprehensive nursing interventions are vital for the successful implementation of recombinant human adenovirus type 5 therapy in this patient population.
The Challenge of Liver Metastasis
Liver metastasis is the leading cause of mortality for patients with gastrointestinal malignancies, with 5-year survival rates often falling below 5%. While surgical resection is the gold standard, 80-90% of these metastases are unresectable at the time of diagnosis.
Oncolytic viruses (OVs)—engineered to selectively infect and lyse tumor cells while sparing healthy tissue—represent a promising frontier in biological therapy. However, the clinical implementation of OVs faces two major hurdles: the technical difficulty of direct intratumoral delivery and the management of the body’s inflammatory response to the virus. This paper addresses the gap in clinical management, proposing a systematic nursing framework to ensure treatment adherence and patient quality of life.
Methods and Procedural Framework
The study prospectively analyzed 47 patients at Ruijin Hospital (Shanghai) between June 2021 and October 2022. Patients received intratumoral injections of a recombinant human adenovirus type 5 (brand name: Ancore), with dosages titrated based on the longest diameter of the target liver lesion. This viral intervention was combined with either chemotherapy plus immunotherapy (23.4%) or chemotherapy plus targeted therapy (76.6%).
A core contribution of this work is the systematic nursing protocol utilized throughout the study. The authors employed an "Evaluation-Diagnosis-Planning-Implementation-Evaluation" model to manage the patient journey, including preoperative nutritional loading, psychological interventions, and rigorous postoperative monitoring of systemic inflammatory markers.
Key Results and Clinical Efficacy
The intervention yielded a disease control rate (DCR) of 74.5% according to RECIST 1.1 criteria. Specifically, 5 patients (10.6%) achieved partial remission (PR), while 30 patients (63.8%) achieved stable disease (SD).
Safety was a primary focus of the analysis. No drug-related deaths occurred. The most frequent adverse effects were fever (78.7%), pain (57.4%), and bone marrow suppression (48.9%). Despite the invasive nature of the injections, 72% of patients maintained Child-Pugh Grade A liver function postoperatively, suggesting the treatment is relatively well-tolerated by the liver parenchyma.
Insights: Nursing as a Clinical Determinant
The authors argue that the efficacy of oncolytic virotherapy is inextricably linked to nursing care. Because OVs trigger a robust immune response, side effects like high fevers (up to 39°C) are common. Without proactive management, these adverse reactions could lead to patient distress and treatment discontinuation.
Furthermore, the study touches on the synergistic potential of OVs. By lysing tumor cells, the virus releases tumor-associated antigens, essentially turning "cold" (immunosuppressive) tumors "hot" and making them more susceptible to the accompanying chemotherapy and immunotherapy. Direct intratumoral injection remains the preferred delivery method to bypass the "neutralization barrier" of antibodies in the bloodstream.
Limitations and Future Work
The authors acknowledge several limitations, including a small sample size (n=47) from a single center and a relatively short 6-month follow-up period. Long-term Overall Survival (OS) data is still needed to determine if the observed stable disease translates into significant life extension. Future research should focus on larger, multi-center trials and the development of next-generation OVs that can better penetrate dense tumor stroma or resist systemic neutralization.
Summary updated